Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

F="http://www.millennium.com" target="_new">http://www.millennium.com . Following the webcast, an archived version of the call will be available at the same address for 30 days.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and JJPRD. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in more than 80 countries worldwide.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and t
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  HealthLoop® released an app version ... in iOS 8 and allows people to share medical ... harnesses native iOS technologies to enhance the HealthLoop experience ... connection with their doctors between visits. ... data they collect is exciting," says HealthLoop founder Dr. ...
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... , Sept. 30, 2014  Georgia-Pacific Professional is ... and tissue for a wide range of away ... its product lines in healthcare, including hospitals, long-term ... Professional is introducing its healthcare products and solutions ... understands the importance of infection control in the ...
Breaking Medicine Technology:HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3
... Dec. 2, 2010 Palatin Technologies, Inc. (NYSE Amex: ... Amex LLC (the "Exchange"), advising Palatin that it is not ... standards under Section 1003 of the Exchange,s Company Guide. ... Palatin was not in compliance with Section 1003(a)(iii) of the ...
... Group is reporting a 35% surge in patients booking in ... the month before Christmas. Many patients are ... made before they return to work in the New Year. ... Breast enlargement , Nose Reshaping, and Liposuction. Lisa ...
Cached Medicine Technology:Palatin Technologies Receives Non-Compliance Letter from NYSE Amex 2Palatin Technologies Receives Non-Compliance Letter from NYSE Amex 3The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas 2
(Date:9/30/2014)... R.I. [Brown University] Autism is no stranger to ... East African nation is access to clinical services, including ... diagnostic measure, for example, validated for use in Swahili, ... new study, however, researchers at Brown University and the ... approach that they implemented at two sites in the ...
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
(Date:9/30/2014)... 2014 Glycodrive , one of ... to help maximize lean, strong muscle growth with a ... of glucose has caught the attention of Shane Michaels, ... behind Glycodrive is to help the body use carbohydrates ... “Carbs are essential in the muscle-building process, and Glycodrive ...
(Date:9/30/2014)... VisitandCare.com reports that revenue ... up more than 79 percent in 2014, marking five ... reported total revenue tripled for its entirety of partnered ... strategy has allowed them to partner with plastic ... comfort and privacy — with state-of-the-art surgical atmospheres aimed ...
(Date:9/30/2014)... A group of Americans is headed to ... that, left unchecked, could create a catastrophic, global pandemic. No, ... Africa. John Rogers, the Executive Director the Eugene Bell Foundation ... a disease most think mankind conquered long ago: tuberculosis. , ... is on the comeback in several countries - what’s especially ...
Breaking Medicine News(10 mins):Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2
... Use of estrogen alone did not increase lung cancer ... online August 13 in The Journal of the ... Health Initiative (WHI) trial, which consisted of several clinical ... previous hysterectomy taking combined estrogen plus progestin therapy had ...
... Reporter , FRIDAY, Aug. 13 (HealthDay News) -- When John D,Amato ... bottle of ibuprofen on the living room floor -- and one ... the pain-reliever container off the coffee table -- where D,Amato had ... pills. "My heart dropped through the floor," he said of ...
... influential medical centers to adopt electronic medical records helps ... Management Insights feature in the current issue of ... for Operations Research and the Management Sciences (INFORMS)., "Social ... Medical Records in U.S. Hospitals" is by Corey M. ...
... over the past 25 years has not translated into ... problems with study design and interpretation, as well as ... 12 in The Journal of the National Cancer ... defines a biomarker as "a characteristic that is objectively ...
... hereditary cancer syndrome may have a role in the regulation of ... the August 15 issue of Genes & Development , a ... called merlin, encoded by the NF2 (neurofibromatosis type 2) gene, controls ... two major types of liver cells. "We found that ...
... HealthDay Reporter , THURSDAY, Aug. 12 (HealthDay News) ... new study finds that many heart patients aren,t all ... in Australia discovered that patients more often preferred boring ... pressure. "Fifty grams of dark chocolate [roughly one ...
Cached Medicine News:Health News:Estrogen not associated with lung cancer incidence and mortality among postmenopausal women 2Health News:Human Meds Are Pets' Biggest Poisoning Danger 2Health News:Human Meds Are Pets' Biggest Poisoning Danger 3Health News:Speed electronic medical record adoption via key medical centers, says Management Science 2Health News:The cancer biomarker conundrum: Too many false discoveries 2Health News:Merlin protein found to control liver stem cells, prevent tumor development 2Health News:Many Patients Say 'No' to Chocolate As Medicine 2Health News:Many Patients Say 'No' to Chocolate As Medicine 3
... elbow, wrist, and hand. Appliance holding patient's ... the opposite shoulder. Abduction can be set ... attaches to pillow wedge at 90 angle. ... along length of arm. Humerus and wrist ...
... Combining the therapeutic benefits of controlled compression ... swelling, and pain. The anatomically designed cuff ... Shoulder Cryo/Cuff can be ordered with an ... larger chest circumferences.,All Cryo/Cuffs can be ordered ...
... comfortable pre-fabricated orthosis is designed for ... third humeral diaphyseal fractures. The lightweight ... soft tissue compression for optimal control ... range-of-motion of both the shoulder and ...
... to treat or help prevent lower ... hip displasia, foot drop, contractures and pressure ... lining provides a comfortable wicking interface for ... easily rotated and locked into a vertical ...
Medicine Products: